- Protocol for the systematic review of the Pneumocystis jirovecii-associated pneumonia in 1
- 2 non-HIV immunocompromised patients
- Mauricio Ernesto Orozco-Ugarriza^{1,4¶}, Yuranis E. Rodger-Cervantes^{3¶}, Yenifer Olivo-3
- 4 Martínez^{1,2¶}
- 5 1 Grupo de investigación en Microbiología y Ambiente (GIMA). Universidad de San
- 6 Buenaventura, Cartagena, Colombia.
- ²Biochemistry and Diseases Research Group, Facultad de Medicina, Universidad de 7
- 8 Cartagena, Cartagena, Colombia.
- 9 ³Graduated from the Bacteriology and Clinical Laboratory Program, Faculty of Health
- Sciences. Universidad de San Buenaventura Cartagena, Colombia. 10
- ⁴Grupo de investigación traslacional en Biomedicina y Biotecnología (GITB&B). Corporación 11
- para el desarrollo de la Investigación en Biomedicina & Biotecnología, Cartagena, Colombia. 12
- 14 Corresponding Author:

- 15 *Mauricio E. Orozco-Ugarriza, Grupo de investigación en Microbiología y Ambiente (GIMA).
- 16 Universidad de San Buenaventura, Cartagena, Colombia. E-mail:
- 17 morozcou@usbcartagena.edu.co, mauricioorozcou@gmail.com.
- These authors contributed equally to this work. 18

Abstract

19

20

21

22

23

24

25

26

27

28

30

32

34

35

36

37

38

39

40

41

42

43

Introduction

Pneumocystis jirovecii pneumonia (PJP) is a well-known and frequent opportunistic infection in

HIV patients. However, there has been an increase in the number of reports of PJP in other

immunosuppressed patients with autoimmune inflammatory disorders or because of

chemotherapy and high doses of steroids, especially when used in combination as part of

immunosuppressive therapy.

Objective

Despite the increasing importance of PJP in non-HIV patients, there is a lack of comprehensive

and updated information on the epidemiology, pathogenesis, diagnosis, microbiology,

treatments, and prophylaxis of this infection in this population. Therefore, the objective of this

systematic review is to synthesize information on these aspects, from a perspective of evidence-

31 based medicine.

Methods

33 The protocol is prepared following the preferred reporting items for systematic reviews and

meta-analyses (PRISMA-P) guidelines. We will perform a systematic review from 2010 to 2022

in PubMed, Google Scholar, ScienceDirect, and Web of Science. In addition, manual searches

will be carried out through related articles, and references to included articles. The main

findings and clinical outcomes were extracted from all the eligible studies with a standardized

instrument. Two authors will independently screen titles and abstracts, review full texts, and

collect data. Disagreements will be resolved by discussion, and a third reviewer will decide if

there is no consensus. We will synthesize the results using a narrative or a meta-analytic

approach, depending on the heterogeneity of the studies.

Expected results

44

- It is expected that this systematic review will provide a comprehensive and up-to-date overview 45
- 46 of the state-of-the-art of PJP in non-HIV patients. Furthermore, the study will highlight possible
- 47 gaps in knowledge that should be addressed through new research.
 - **Conclusions**
- 49 Here, we present the protocol for a systematic review which will consider all existing evidence
- 50 from peer-reviewed publication sources relevant to the primary and secondary outcomes related
- 51 to diagnosing and managing PJP in non-HIV patients.
- 52 **Systematic review registry**
- 53 This study was registered at the International Prospective Registry for Systematic Reviews
- 54 (PROSPERO registration number: CRD42023429112)
- 55 **Keywords:** Pneumocystis jirovecii pneumonia (PJP), Pneumocystis jirovecii, Non-HIV,
- immunocompromised host. 56

Introduction

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

Pneumocystis jirovecii pneumonia (PJP) is a fungal infection that mainly affects patients with immune system disorders. It is a severe and potentially fatal disease, especially in immunocompromised patients. One of the most common causes of immunosuppression is human immunodeficiency virus (HIV) infection, which is strongly associated with PJP [1]. However, in recent years, the incidence of PJP has decreased in HIV patients is around 10-20% [2], due to antiretroviral therapy and routine prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) [3]. In contrast, the prevalence of PJP has risen steadily and has emerged as a major cause of morbidity and mortality among patients with non-HIV immunosuppression [4]. These patients have different causes of immune system alterations that can increase the risk of developing PJP, such as hematological or solid malignancies [5], organ transplantation [2], inflammatory or autoimmune diseases [6], as well as immunosuppressive treatments [6,7]. The clinical presentation of PJP may differ between patients with and without HIV infection [8], which may influence early detection and initiation of appropriate treatment [9]. Studies have shown that PJP in non-HIV patients experiences a more progressive clinical course, a poor prognosis, and a higher mortality rate (ranging from 30% to 60%) than in HIV patients [4,10]. This is due to several factors, such as delay in diagnosis, lack of prevention, advanced age, comorbidities, and immunosuppression. Therefore, early diagnosis is key to allowing evaluation of the patient's clinical status and choice of the best anti-PJP therapy, which may include TMP-SMX or other options, as appropriate, to improve prognosis [11]. The prevention and management of PJP in non-HIV patients remain a challenge in the medical field. There is currently no standard guideline for the prophylaxis of this infection in this group, and the decision to start prophylaxis depends on the individual risk-benefit assessment for each patient [4]. It is essential to improve our understanding of the risk factors and to carry out a personalized evaluation of the patients [12]. An early diagnosis and

appropriate therapy can make a difference in the prognosis of the disease [13]. Several studies have identified risk factors for PJP in non-HIV patients, such as the concomitant use of corticosteroids and immunosuppressants, lymphopenia, and a CD4+ T cell count below 200 cells/µL [14,15]. However, it is crucial to highlight that the CD4+ T cell count, used as an indicator of immune function and the risk of developing opportunistic infections in HIV patients, is not a reliable criterion for the prophylaxis of PJP in non-HIV patients [4,10]. This is because it can vary depending on the cause of immunosuppression and not reflect the actual immune status of the patient [16].

The diagnosis of PJP is based on clinical presentation, radiological findings, and confirmation by observing the organisms in stained respiratory samples [17]. However, *P. jirovecii* is extremely difficult to cultivate *in vitro*, which poses significant challenges in the diagnosis, treatment, and prevention of the disease. Despite these difficulties, there are currently more efficient laboratory tools for the diagnosis of *P. jirovecii*, such as polymerase chain reaction (PCR) and immunofluorescence assays, which have improved our ability to identify cases of PJP [13,18]. However, due to the difficulty of cultivating this organism *in vitro* conditions, our understanding of numerous aspects of pneumocystosis, including the host immune responses to the organism and the immunopathology of this infection, remains limited [19]. Given this limitation, the current information on the basic aspects of PJP has been obtained mainly from some limited clinical studies and experiments in rodent models [20]. These sources of information may not fully reflect the reality of PJP in human patients, so more research is required to improve the diagnosis, prevention, and treatment of this infection.

Considering the serious consequences of PJP in immunocompromised patients due to causes other than HIV, in this article, we present a protocol to perform a systematic review. This systematic review aims to synthesize information on the epidemiology, pathogenesis, diagnosis, microbiology, treatments, and prophylaxis of PJP in these patients, from an evidence-based medicine perspective. This systematic review is expected to provide clarity on the current state

of knowledge and identify research gaps, ultimately contributing to better management of PJP in non-HIV patients.

Methods

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

Design and registration

This systematic review protocol has been conducted following the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA-P) guidelines [21]. This review protocol was registered in the Prospective Register of Systematic Reviews platform (PROSPERO) [22], (registration number CRD42023429112), and can be accessed at https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023429112. See (S1 Checklist) for the completed PRISMA-P checklist. We will only make changes to the study protocol if necessary and we will report them in the PROSPERO record.

Search strategy

The search strategy will be conducted comprehensively across electronic databases. including PubMed, Google Scholar, ScienceDirect, and Web of Science. Controlled terms (also known as Medical Subject Headings or MeSH terms) and relevant keywords will be used to identify relevant studies related to Pneumocystis jirovecii-associated pneumonia in non-HIV immunosuppression, such "Pneumocystis jirovecii", "Pneumocystis carinii", "pneumonia", "non-HIV", diagnosis", "pneumocystosis", "without HIV "immunocompromised", "immunosuppression", "cancer", "transplantation", "autoimmune", and "inflammatory", "incidence", "clinical characteristics", "risk factors" and "therapeutic management".

We will use Boolean operators (such as AND, OR, NOT) and filters to refine the search results. We will also perform manual searches through related articles, and references of included articles, to identify additional relevant studies.

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

and adverse effects.

The pilot search will be adapted to each database, avoiding any inconsistencies that may affect data extraction and ensuring that the final search strategy is correctly adapted. The details of the search strategy, including the terms used and filters applied, will be recorded to ensure transparency and reproducibility of the systematic review. A sample search strategy for PubMed is available as supporting information (S2 File). Full search strategies will be provided in the complete review. Eligibility criteria We will include studies that meet the following criteria: Population: Patients with non-HIV immunosuppression, defined as having any condition or treatment that alters the immune system function, such as hematological or solid malignancies, organ transplantation, inflammatory or autoimmune diseases, or immunosuppressive drugs. Intervention: Any intervention for the diagnostic, therapeutic, or prophylactic measure for PJP, such as laboratory tests; radiological exams; antifungal drugs; and preventive measures. The type, duration, frequency, dosage, route, or any other relevant characteristic of the measure will be specified, respectively. Exposure: Any risk factor, cause, agent, or situation associated with PJP, such as immunosuppression, organ transplantation, autoimmune diseases, corticosteroid use, exposure to the *P. jirovecii fungus*, or underlying medical conditions, immunosuppressive therapies, environmental exposures, or genetic predisposition, will be specified for type, duration, frequency, dosage, route, or any other relevant characteristic. Comparator: We will have two types of comparators including 1) HIV patients with PJP, the most well-known and common group affected by this infection. 2) Any comparator for the intervention, such as different tests, drugs, doses, durations, or strategies. Outcome: Any outcome related to PJP, such as incidence, prevalence, mortality, morbidity,

Study design: We will include original articles with an observational and interventional design, as well as systematic reviews and meta-analyses, that report data on PJP in non-HIV patients and outcomes of interest (incidence, clinical characteristics, risk factors, and therapeutic management). We will exclude case reports, case series, letters, editorials, and reviews that do not provide original data.

Publication date: The search will be limited to studies published between 2010 and 2022, aiming to capture the most up-to-date evidence on PJP in non-HIV patients.

Language: We will include studies published in English or Spanish, as these are the languages that the reviewers can read and understand. However, efforts will be made to identify and access relevant studies published in other languages if possible.

Literature screening and study selection

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

We plan to make use of a flow diagram to summarize the article screening process and detail the reasons for the exclusion of studies screened as full text. This will follow the PRISMA guidelines for reporting systematic reviews [23]. The report will feature a PRISMA-compliant flow chart illustrating the process of study screening and selection, as depicted in the S3 file.

All studies retrieved by the searches will be combined using the Mendeley software desktop, and duplicates will be removed. All articles returned by the search procedure will be divided between the authors (MEOU and YRC), who will independently conduct a 3-step screening (titles, abstracts, and full texts) and decide on their inclusion or exclusion. Any disagreement between the reviewers will be resolved by discussion, and a third reviewer (YOM) will decide if there is no consensus.

Data extraction

Data will be collected independently by three individual reviewers from each eligible publication, and the extracted data items, using a standardized data extraction form (See S4 File). The data will be exported to Excel (the spreadsheet software). After completing the

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

selection and screening of the studies, data extraction will be conducted in four stages: 1) development of a data extraction form, 2) peer-review of the data extraction form, 3) pilot test of the data extraction form, and 4) final data extraction. Data items The following data items will be extracted from the included studies: Identification of the study: This will include the name of the journal, article DOI, article title, authors, publication year, short citation, and country. Methods: This will include the study objectives, study design, inclusion and exclusion criteria, intervention (type, dose, duration, frequency, mode of administration), intervention characteristics, comparator characteristics (if applicable), diagnostic methods, participant demographics (mean age, sex, number of participants), and description of effect and effect size (if applicable), and results (summary statistics, effect estimates, confidence intervals, p-values, subgroup analyses, sensitivity analyses, risk of bias, quality of evidence). Main findings: This will include diagnosis, patient characteristics, and other relevant clinical outcome measures (definition, assessment, time point). One-sentence conclusion of the study. Methodological quality assessment For the systematic review, the method of assessing the risk of bias or study quality will involve the following steps: Independent assessment: Two reviewers (MEOU and YRC), will independently evaluate the methodological quality of the included studies or literature. Disagreement resolution: Any disagreements between reviewers' assessments will be resolved through discussion and consensus, in cases where consensus cannot be reached, a third reviewer (YOM) will be involved to reach a final agreement.

Study selection and data extraction: Two reviewers will independently assess the search results and select high-quality literature for inclusion in the review. Multiple reviewers will be involved in the data extraction process, to minimize the risk of errors.

Blinding: The study selection, data extraction, and risk of bias assessment will be performed without blinding the assessors to the study authors or the journal of publication.

These measures are implemented to ensure the rigor and reliability of the review process. By involving multiple independent reviewers and resolving disagreements through discussion and consensus, the risk of bias in the included studies will be assessed transparently and comprehensively.

Strategy for data synthesis

We plan to synthesize the data using a systematic narrative synthesis approach, to provide a comprehensive view of the topic by presenting a coherent narrative that integrates the primary findings from the included studies. This synthesis will involve summarizing data extracted from the included studies, with a specific focus on clinical characteristics, risk factors, therapeutic treatments, and other interventions, as well as the methodological quality of the studies and any identified limitations. When appropriate, we will categorize these findings into relevant groups to facilitate a clearer presentation of the synthesized data. Additionally, we will employ descriptive statistics to analyze the results, where feasible. These measures will contribute to a comprehensive and coherent synthesis of the data, enabling a deeper understanding of the topic, its clinical implications, and the quality of the underlying evidence.

Ethics

This is a systematic review that will use published data and does not require ethical approval.

Status of the study and dissemination plan

We are currently selecting the records based on the eligibility criteria applied to the titles and abstracts. This systematic review is ongoing, and we expect to complete the project, publish the results in a peer-reviewed journal, and report them in 12 months. We will follow the updated PRISMA guideline to report the final paper and register it on the PROSPERO website. All the data will be accessible as supplementary information when the review is completed. Moreover, we will also present the main findings at academic conferences and relevant professional meetings.

Discussion

In this systematic review protocol, a detailed plan of all steps of the review has been described, including protocol development, search strategy, study selection, data extraction, quality assessment, and synthesis of data, to ensure the production of unbiased evidence on PJP in patients with non-HIV immunosuppression, its clinical characteristics, risk factors, treatments, and available interventions. The knowledge obtained from this review can contribute to better prevention, diagnosis, and management of this disease, which has increased its incidence and mortality in recent years. Furthermore, it can identify existing knowledge gaps and suggest possible future lines of research.

Conclusion

The PJP is a serious and potentially fatal opportunistic infection that affects immunocompromised patients, especially those who are not infected by HIV. The diagnosis and management of PJP in non-HIV patients pose significant challenges, as there are no clear guidelines or consensus on the optimal strategies. Therefore, it is important to conduct a systematic review that synthesizes the available evidence on the clinical characteristics, risk factors, treatments, and interventions for PJP in non-HIV patients. In this protocol, we describe the methods and criteria that we will use to perform a comprehensive and up-to-date search, selection, extraction, quality assessment, and synthesis of data from peer-reviewed publications

relevant to the primary and secondary outcomes of interest. We expect that this systematic review will provide a state-of-the-art overview of the current knowledge and practice of PJP in non-HIV patients, as well as identify the existing knowledge gaps and suggest possible future lines of research.

258

259

260

262	Supporting information
263	S1 Checklist. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols
264	(PRISMA-P checklist).
265	(PDF)
266	S2 File. Sample search strategy for PubMed.
267	(DOCX)
268	S3 File. PRISMA 2009 flow diagram.
269	(DOCX)
270	S4 File. Data extraction form for systematic review.
271	(DOCX)
272	S5 File. PROSPERO registration.
273	(PDF)
274	Acknowledgments
275	The authors would like to thank all members of the group for their support and help.
276	
277	
278	
279	
280	
281	
282	

283 **Author contributions** 284 Conceptualization: Mauricio Ernesto Orozco-Ugarriza, Yuranis E. Rodger-Cervantes, Yenifer 285 Olivo-Martínez 286 Data curation: Mauricio Ernesto Orozco-Ugarriza, Yuranis E. Rodger-Cervantes, Yenifer Olivo-287 Martínez 288 Investigation: Yuranis E. Rodger-Cervantes 289 Methodology: Mauricio Ernesto Orozco-Ugarriza, Yuranis E. Rodger-Cervantes, Supervision: Mauricio Ernesto Orozco-Ugarriza 290 291 Validation: Mauricio Ernesto Orozco-Ugarriza, Yuranis E. Rodger-Cervantes, Yenifer Olivo-292 Martínez 293 Visualization: Mauricio Ernesto Orozco-Ugarriza, Yuranis E. Rodger-Cervantes, Yenifer Olivo-294 Martínez 295 Writing - original draft: Mauricio Ernesto Orozco-Ugarriza, Yuranis E. Rodger-Cervantes, 296 Yenifer Olivo-Martínez 297 Writing – review and editing: Mauricio Ernesto Orozco-Ugarriza, Yuranis E. Rodger-Cervantes, Yenifer Olivo-Martínez 298 299 All authors read and approved the final manuscript. 300 **Funding** 301 No funding was received for the development of this protocol. 302 Availability of data and materials 303 All data from this study will be made available in the online databases upon study completion. 304 Ethics approval and consent to participate. 305 This study has no ethics approval needed.

\sim			
('An	cent to	ır nııh	lication
CUII	schi it	n bub	псанон

306

308

No need for consent for research and publication. 307

Competing interests

309 The authors declare that they have no competing interests.

References

- 311 1. Hof H. Pneumocystis jirovecii: A peculiar fungus posing particular problems for therapy
- and prophylaxis. Mycoses. 2012;55. doi:10.1111/j.1439-0507.2011.02159.x
- Duan J, Gao J, Liu Q, Sun M, Liu Y, Tan Y, et al. Characteristics and Prognostic Factors
- 314 of Non-HIV Immunocompromised Patients With Pneumocystis Pneumonia Diagnosed
- by Metagenomics Next-Generation Sequencing. Front Med (Lausanne). 2022;9.
- 316 doi:10.3389/fmed.2022.812698
- 317 3. Castro JG, Morrison-Bryant M. Management of *Pneumocystis jirovecii* pneumonia in
- 318 HIV infected patients: Current options, challenges and future directions. HIV/AIDS -
- Research and Palliative Care. 2010;2. doi:10.2147/hiv.s7720
- 320 4. Huang L, Xu S, Huang Z, Chen Y, Xu N, Xie B. Risk factors associated with
- 321 Pneumocystis jirovecii pneumonia in non-HIV immunocompromised patients and co-
- pathogens analysis by metagenomic next-generation sequencing. BMC Pulm Med.
- 323 2023;23. doi:10.1186/s12890-022-02300-8
- 324 5. Kofteridis DP, Valachis A, Velegraki M, Antoniou M, Christofaki M, Vrentzos GE, et
- al. Predisposing factors, clinical characteristics and outcome of *Pneumocystis jirovecii*
- pneumonia in HIV-negative patients. Journal of Infection and Chemotherapy. 2014;20.
- 327 doi:10.1016/j.jiac.2014.03.003
- 328 6. Chan SCW, Chung HY, Lau CS, Li PH. Epidemiology, mortality and effectiveness of
- prophylaxis for *Pneumocystis jiroveci* pneumonia among rheumatic patients: a territory-
- 330 wide study. Ann Clin Microbiol Antimicrob. 2021;20. doi:10.1186/s12941-021-00483-2
- 331 7. Xia S, Gong H, Wang YK, Liu L, Zhao YC, Guo L, et al. Pneumocystis jirovecii
- pneumonia associated with immune checkpoint inhibitors: A systematic literature review
- of published case reports and disproportionality analysis based on the FAERS database.
- Front Pharmacol. 2023;14. doi:10.3389/fphar.2023.1129730
- 335 8. Nasr M, Mohammad A, Hor M, Baradeiya AM, Qasim H. Exploring the Differences in
- Pneumocystis Pneumonia Infection Between HIV and Non-HIV Patients. Cureus. 2022.
- 337 doi:10.7759/cureus.27727
- 338 9. Kim TO, Lee JK, Kwon YS, Kim Y II, Lim SC, Kim MS, et al. Clinical characteristics
- and prognosis of patients with Pneumocystis jirovecii pneumonia without a
- compromised illness. PLoS One. 2021;16. doi:10.1371/journal.pone.0246296

- 10. Merrill ME, Simonetti JA. Risk of and prophylaxis against PCP pneumonia among HIV-341
- uninfected individuals. J Gen Intern Med. 2018;33. 342
- 343 11. Assal M, Lambert J, Chow-Chine L, Bisbal M, Servan L, Gonzalez F, et al. Prognostic
- 344 impact of early adjunctive corticosteroid therapy in non-HIV oncology or haematology
- 345 patients with *Pneumocystis jirovecii* pneumonia: A propensity score analysis. PLoS One.
- 346 2021;16. doi:10.1371/journal.pone.0250611
- 347 12. Ghembaza A, Vautier M, Cacoub P, Pourcher V, Saadoun D. Risk Factors and
- Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and 348
- 349 Inflammatory Diseases. Chest. 2020. doi:10.1016/j.chest.2020.05.558
- Li MC, Lee NY, Lee CC, Lee HC, Chang CM, Ko WC. Pneumocystis jiroveci 350 13.
- pneumonia in immunocompromised patients: Delayed diagnosis and poor outcomes in 351
- non-HIV-infected individuals. Journal of Microbiology, Immunology and Infection. 352
- 2014;47. doi:10.1016/j.jmii.2012.08.024 353
- 354 14. Watanabe Y, Hayashi K, Terai S. A Rare Case of Ulcerative Colitis with Severe
- Pneumocystis jirovecii Pneumonia and Cytomegalovirus Colitis: A Case Report and 355
- 356 Literature Review. Internal Medicine. 2022. doi:10.2169/internalmedicine.7953-21
- 357 15. Viceconte G, Buonomo AR, D'Agostino A, Foggia M, Di Fusco A, Pinchera B, et al.
- Risk Factors for Pneumocystis jirovecii Pneumonia in Non-HIV Patients Hospitalized 358
- 359 COVID-19: Case-Control Study. Fungi. 2023;9. for **Journal** of
- doi:10.3390/jof9080838 360
- 361 Atkinson A, Miro JM, Mocroft A, Reiss P, Kirk O, Morlat P, et al. No need for 16.
- 362 secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with
- 363 HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than
- 364 100 cells/μL. J Int AIDS Soc. 2021;24. doi:10.1002/jia2.25726
- 365 17. Dunbar A, Schauwvlieghe A, Algoe S, van Hellemond JJ, Revnders M, Vandecasteele S,
- 366 et al. Epidemiology of *Pneumocystis jirovecii* Pneumonia and (Non-)use of Prophylaxis.
- Front Cell Infect Microbiol. 2020;10. doi:10.3389/fcimb.2020.00224 367
- 18. Grønseth S, Rogne T, Hannula R, Åsvold BO, Afset JE, Damås JK. Epidemiological and 368
- clinical characteristics of immunocompromised patients infected with *Pneumocystis* 369
- 370 jirovecii in a twelve-year retrospective study from Norway. BMC Infect Dis. 2021;21.
- 371 doi:10.1186/s12879-021-06144-1

372 19. Charpentier E, Ménard S, Marques C, Berry A, Iriart X. Immune response in 373 pneumocystis infections according to the host immune system status. Journal of Fungi. 374 2021. doi:10.3390/jof7080625 375 20. Elsegeiny W, Zheng M, Eddens T, Gallo RL, Dai G, Trevejo-Nunez G, et al. Murine 376 models of Pneumocystis infection recapitulate human primary immune disorders. JCI 377 Insight. 2018;3. doi:10.1172/jci.insight.91894 378 21. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred 379 reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 380 statement. Syst Rev. 2015;4: 1. doi:10.1186/2046-4053-4-1 22. Schiavo JH. PROSPERO: An International Register of Systematic Review Protocols. 381 Medical Reference Services Quarterly. 2019. doi:10.1080/02763869.2019.1588072 382 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The 383 23. 384 PRISMA 2020 statement: An updated guideline for reporting systematic reviews. The

BMJ. 2021. doi:10.1136/bmj.n71

385